Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced that Roche renewed the licensing agreement of Genedata Expressionist for Mass Spectrometry. Genedata Expressionist is a comprehensive, enterprise-level system for omics data management. Roche will use the system to target molecular pathways and validate novel biomarkers in the field of proteomics.
"Genedata Expressionist for Mass Spectrometry efficiently supports understanding of disease mechanisms, discovery and validation of biomarkers," explained Prof. Hanno Langen, head of the Protein and Metabolite Technologies Group at Roche. "We process and analyze extremely large data sets and therefore require reliable, high-throughput, and scalable software to support our innovative mass spec processes. Genedata Expressionist for Mass Spectrometry gives us automated, workflow-based processing and powerful visualizations - all of which enables our high-quality biomarker identification process."
Thriving on large experimental data sets, Genedata Expressionist for Mass Spectrometry integrates a range of mass spectrometry (MS) technologies including label-free LC-MS/GC-MS, labeled experiments using SILAC, iTRAQ, and TMT, MRM, and Infusion MS. It also provides a rich portfolio of statistical tools that promote understanding of biological systems and diseases. Workflow support includes:
* Fragment Analysis
* 4D Data Experiments
* Targeted Analysis
* Peptide and Protein Identification with Mascot, SEQUEST, X!Tandem, and TPP
"Using Genedata Expressionist helps us to efficiently support the complex data flow and analysis of the mass spectrometry experiments. Our experience with the software and the company is positive," noted Dr. Martin Erkens, head of Early Development Informatics, pRED.
"Roche is pioneering personalized healthcare and we take great pride in contributing to this innovative work," said Dr. Othmar Pfannes, CEO of Genedata. "Moreover, Roche's use of Genedata Expressionist validates it as the platform of choice for integrated, large-scale data management in biomarker discovery for personalized healthcare."